282 related articles for article (PubMed ID: 23974278)
1. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
2. [The expression of MRP, GST-pi, Topo IIalpha and COX-2 in epithelial ovarian cancer and its relationship to drug resistance and prognosis].
Cao DY; Shen K; Yang JX; Guan J
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(25):1738-41. PubMed ID: 17919376
[TBL] [Abstract][Full Text] [Related]
3. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
4. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
Ferrandina G; Petrillo M; Carbone A; Zannoni G; Martinelli E; Prisco M; Pignata S; Breda E; Savarese A; Scambia G
Br J Cancer; 2008 Jun; 98(12):1910-5. PubMed ID: 18506140
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
7. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma.
Qian X; Xi X; Li L
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):126-32. PubMed ID: 20724919
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
9. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
11. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
Kimura F; Kawamura J; Watanabe J; Kamoshida S; Kawai K; Okayasu I; Kuwao S
Diagn Cytopathol; 2010 Mar; 38(3):161-7. PubMed ID: 19821496
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.
Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Weichert W; Noske A; Budczies J; Müller BM; Buckendahl AC; Röske A; Eldin Elwali N; Dietel M; Denkert C
Mod Pathol; 2009 Apr; 22(4):579-88. PubMed ID: 19270648
[TBL] [Abstract][Full Text] [Related]
13. Mitosin and DNA topoisomerase IIalpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival.
Korkolopoulou P; Patsouris E; Konstantinidou AE; Christodoulou P; Thomas-Tsagli E; Kouzelis K; Angelidakis D; Rologis D; Davaris P
Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):207-14. PubMed ID: 11556747
[TBL] [Abstract][Full Text] [Related]
14. Nuclear receptor DAX-1 in human common epithelial ovarian carcinoma: an independent prognostic factor of clinical outcome.
Abd-Elaziz M; Akahira J; Moriya T; Suzuki T; Yaegashi N; Sasano H
Cancer Sci; 2003 Nov; 94(11):980-5. PubMed ID: 14611675
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma].
Ferariu D; Danciu M; Ciobanu D; Zugun F; Florea N; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):738-43. PubMed ID: 20201262
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
Taniguchi K; Wakabayashi T; Yoshida T; Mizuno M; Yoshikawa K; Kikuchi A; Nakashima N; Yoshida J
J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.
Rudolph P; MacGrogan G; Bonichon F; Frahm SO; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM; Parwaresch R
Breast Cancer Res Treat; 1999 May; 55(1):61-71. PubMed ID: 10472780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
